Efficacy of varenicline for smoking cessation [1]

JAMA

Volumn 296, Issue 21, 2006, Pages 2555-

  Dervaux, Alain ^a   Kanit, Mostafa ^a   Laqueille, Xavier ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; VARENICLINE;

CIGARETTE SMOKING; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; MENTAL DISEASE; PRIORITY JOURNAL; SMOKING CESSATION; STRUCTURED INTERVIEW;

EID: 33845397552     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.21.2555-a     Document Type: Letter

References (5)

1. Gonzales D, Rennard SI, Nides M, et al; for the Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
2. Jorenby DE, Hays JT, Rigotti NA, et al; for the Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
3. Tonstad S, Tonnesen P, Hajek P, et al; for the Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.
4. Leonard S, Adler LE, Benhammou K, et al. Smoking and mental illness. Pharmacol Biochem Behav. 2001;70:561-570.
5. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284: 2606-2610.